Chondrocyte knee disorder therapy - Isto Biologics
Alternative Names: DeNovo ET; Neocartilage; RevaFlexLatest Information Update: 09 Aug 2019
Price :
$50 *
At a glance
- Originator ISTO Technologies
- Developer Isto Biologics
- Class Cell therapies
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cartilage disorders
Most Recent Events
- 09 Aug 2019 Discontinued - Phase-III for Cartilage disorders in USA (Intra-articular)
- 10 Mar 2016 Chondrocyte knee disorder therapy is still in phase III trials for Cartilage disorders in USA (Intra-articular)
- 07 Feb 2012 Phase-III clinical trials in Cartilage disorders in USA (Intra-articular)